An ancillary study of participants in a randomized, placebo-controlled trial suggests that ingestion of bovine lactoferrin promotes expression of interferon alpha in the human colon

Journal of Functional Foods

Volumn 10, Issue , 2014, Pages 305-317

  Alexander, David B ^a   Iigo, Masaaki ^a   Hamano, Hirokazu ^b   Kozu, Takahiro ^c   Saito, Yutaka ^d   Saito, Daizo ^e   Kakizoe, Tadao ^f   Xu, Jiegou ^a   Yamauchi, Koji ^b   Takase, Mitsunori ^b   Suzui, Masumi ^a   Tsuda, Hiroyuki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b MORINAGA MILK INDUSTRY CO LTD   (Japan)

^c Toyosu Cubic Garden Kozu Clinic   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e Nihonbashi Daizo Clinic   (Japan)

^f Japan Cancer Society   (Japan)

Author keywords

Human interferon alpha; Human intestine; Ingestion of bovine lactoferrin

Indexed keywords

ANIMALIA; BOVINAE;

EID: 84919983358     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2014.06.028     Document Type: Article

References (41)

1. Abreu M.T., Fukata M., Arditi M. TLR signaling in the gut in health and disease. The Journal of Immunology 2005, 174:4453-4460.
2. Alexander D.B., Iigo M., Yamauchi K., Suzui M., Tsuda H. Lactoferrin: An alternative view of its role in human biological fluids. Biochemistry and Cell Biology=Biochimie et Biologie Cellulaire 2012, 90:279-306.
3. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nature Reviews. Immunology 2008, 8:411-420.
4. Bekisz J., Baron S., Balinsky C., Morrow A., Zoon K.C. Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals 2010, 3:994-1015.
5. Brassard D.L., Grace M.J., Bordens R.W. Interferon-alpha as an immunotherapeutic protein. Journal of Leukocyte Biology 2002, 71:565-581.
6. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) Scientific Opinion on bovine lactoferrin. EFSA Journal 2012, 10:2701.
7. Hall J.A., Bouladoux N., Sun C.M., Wohlfert E.A., Blank R.B., Zhu Q., Grigg M.E., Berzofsky J.A., Belkaid Y. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 2008, 29:637-649.
8. Hervas-Stubbs S., Perez-Gracia J.L., Rouzaut A., Sanmamed M.F., Le Bon A., Melero I. Direct effects of type I interferons on cells of the immune system. Clinical Cancer Research: An official journal of the American Association for Cancer Research 2011, 17:2619-2627.
9. Iigo M., Alexander D.B., Long N., Xu J., Fukamachi K., Futakuchi M., Takase M., Tsuda H. Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine. Biochimie 2009, 91:86-101.
10. Iigo M., Alexander D.B., Xu J., Futakuchi M., Suzui M., Kozu T., Akasu T., Saito D., Kakizoe T., Yamauchi K., Abe F., Takase M., Sekine K., Tsuda H. Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine. Biometals: An International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine 2014, 10.1007/s10534-014-9747-2.
11. Iigo M., Shimamura M., Matsuda E., Fujita K., Nomoto H., Satoh J., Kojima S., Alexander D.B., Moore M.A., Tsuda H. Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa: A possible explanation for inhibition of carcinogenesis and metastasis. Cytokine 2004, 25:36-44.
12. Iwasa M., Kaito M., Ikoma J., Takeo M., Imoto I., Adachi Y., Yamauchi K., Koizumi R., Teraguchi S. Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b. The American Journal of Gastroenterology 2002, 97:766-767.
13. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nature Immunology 2010, 11:373-384.
14. Kawai T., Sato S., Ishii K.J., Coban C., Hemmi H., Yamamoto M., Terai K., Matsuda M., Inoue J., Uematsu S., Takeuchi O., Akira S. Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nature Immunology 2004, 5:1061-1068.
15. Korhonen H. Milk-derived bioactive peptides: From science to applications. Journal of Functional Foods 2009, 1:177-187.
16. Kozu T., Iinuma G., Ohashi Y., Saito Y., Akasu T., Saito D., Alexander D.B., Iigo M., Kakizoe T., Tsuda H. Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prevention Research 2009, 2:975-983.
17. Kuhara T., Iigo M., Itoh T., Ushida Y., Sekine K., Terada N., Okamura H., Tsuda H. Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutrition and Cancer 2000, 38:192-199.
18. Kuhara T., Yamauchi K., Tamura Y., Okamura H. Oral administration of lactoferrin increases NK cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. Journal of Interferon and Cytokine Research: The official journal of the International Society for Interferon and Cytokine Research 2006, 26:489-499.
19. Lande R., Giacomini E., Grassi T., Remoli M.E., Iona E., Miettinen M., Julkunen I., Coccia E.M. IFN-alpha beta released by Mycobacterium tuberculosis-infected human dendritic cells induces the expression of CXCL10: Selective recruitment of NK and activated T cells. The Journal of Immunology 2003, 170:1174-1182.
20. Lewis M.A., Hayes T.G. Talactoferrin immunotherapy in metastatic renal cell carcinoma: A case series of four long-term survivors. Journal of Clinical Medicine Research 2011, 3:47-51.
21. Mancuso G., Midiri A., Biondo C., Beninati C., Zummo S., Galbo R., Tomasello F., Gambuzza M., Macri G., Ruggeri A., Leanderson T., Teti G. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. The Journal of Immunology 2007, 178:3126-3133.
22. McIntosh G.H., Regester G.O., Le Leu R.K., Royle P.J., Smithers G.W. Dairy proteins protect against dimethylhydrazine-induced intestinal cancers in rats. The Journal of Nutrition 1995, 125:809-816.
23. Megjugorac N.J., Young H.A., Amrute S.B., Olshalsky S.L., Fitzgerald-Bocarsly P. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. Journal of Leukocyte Biology 2004, 75:504-514.
24. Mozzanica N., Cattaneo A., Boneschi V., Brambilla L., Melotti E., Finzi A.F. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon. Archives of Dermatological Research 1990, 282:311-317.
25. O'Hara A.M., Shanahan F. The gut flora as a forgotten organ. EMBO Reports 2006, 7:688-693.
26. Okada S., Tanaka K., Sato T., Ueno H., Saito S., Okusaka T., Sato K., Yamamoto S., Kakizoe T. Dose-response trial of lactoferrin in patients with chronic hepatitis C. Japanese Journal of Cancer Research: Gann 2002, 93:1063-1069.
27. Paun A., Reinert J.T., Jiang Z., Medin C., Balkhi M.Y., Fitzgerald K.A., Pitha P.M. Functional characterization of murine interferon regulatory factor 5 (IRF-5) and its role in the innate antiviral response. The Journal of Biological Chemistry 2008, 283:14295-14308.
28. Pestka S. The interferons: 50years after their discovery, there is much more to learn. The Journal of Biological Chemistry 2007, 282:20047-20051.
29. Pichlmair A., Reis e Sousa C. Innate recognition of viruses. Immunity 2007, 27:370-383.
30. Spadaro M., Curcio C., Varadhachary A., Cavallo F., Engelmayer J., Blezinger P., Pericle F., Forni G. Requirement for IFN-gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors. Cancer Research 2007, 67:6425-6432.
31. Takakura N., Wakabayashi H., Yamauchi K., Takase M. Influences of orally administered lactoferrin on IFN-gamma and IL-10 production by intestinal intraepithelial lymphocytes and mesenteric lymph-node cells. Biochemistry and Cell Biology=Biochimie et Biologie Cellulaire 2006, 84:363-368.
32. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
33. Theofilopoulos A.N., Baccala R., Beutler B., Kono D.H. Type I interferons (α/β) in immunity and autoimmunity. Annual Review of Immunology 2005, 23:307-336.
34. Trinchieri G. Type I interferon: Friend or foe?. The Journal of Experimental Medicine 2010, 207:2053-2063.
35. Tsuda H., Kozu T., Iinuma G., Ohashi Y., Saito Y., Saito D., Akasu T., Alexander D.B., Futakuchi M., Fukamachi K., Xu J., Kakizoe T., Iigo M. Cancer prevention by bovine lactoferrin: From animal studies to human trial. Biometals: An International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine 2010, 23:399-409.
36. Ueno H., Sato T., Yamamoto S., Tanaka K., Ohkawa S., Takagi H., Yokosuka O., Furuse J., Saito H., Sawaki A., Kasugai H., Osaki Y., Fujiyama S., Sato K., Wakabayashi K., Okusaka T. Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Science 2006, 97:1105-1110.
37. Vitetta L., Coulson S., Beck S.L., Gramotnev H., Du S., Lewis S. The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: A double blind randomized study. Complementary Therapies in Medicine 2013, 21:164-171.
38. Wakabayashi H., Takakura N., Yamauchi K., Tamura Y. Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clinical and Vaccine Immunology: CVI 2006, 13:239-245.
39. Wang W.P., Iigo M., Sato J., Sekine K., Adachi I., Tsuda H. Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin. Japanese Journal of Cancer Research: Gann 2000, 91:1022-1027.
40. Yrlid U., Milling S.W., Miller J.L., Cartland S., Jenkins C.D., MacPherson G.G. Regulation of intestinal dendritic cell migration and activation by plasmacytoid dendritic cells, TNF-alpha and type 1 IFNs after feeding a TLR7/8 ligand. The Journal of Immunology 2006, 176:5205-5212.
41. Zheng Y., Valdez P.A., Danilenko D.M., Hu Y., Sa S.M., Gong Q., Abbas A.R., Modrusan Z., Ghilardi N., de Sauvage F.J., Ouyang W. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nature Medicine 2008, 14:282-289.